Literature DB >> 1700161

Comparison of a polyclonal and monoclonal immunoassay for PSA: need for an international antigen standard.

H C Graves1, N Wehner, T A Stamey.   

Abstract

Two leading commercial immunoassays for prostate specific antigen (the Yang Laboratories polyclonal radioimmunoassay and the Hybritech two-site monoclonal radioimmunometric assay) were compared using independently purified antigen as the calibrator. The Yang polyclonal assay yielded values from 1.4 to 1.9 times higher than the Hybritech monoclonal assay on the same sample, similar to results of previous investigators. When an independent prostate specific antigen calibrator was substituted for the respective kit calibrators, both assays yielded essentially identical results, thereby confirming that differences in assay values arise from differences in the assigned values of the kit calibrators. Otherwise, both assays had similar responses in the high and low range. Recovery studies of prostate specific antigen in various diluents demonstrated that antigen recovery was lowest in diluents with the highest protein content. We conclude that the kit manufacturers have assigned different values to their antigen calibrators. Sample values between the assays can be compared by use of an appropriate conversion table. Differences in their recommended ranges of normal for prostate specific antigen in male serum (zero to 2.5 ng./ml. for the Yang assay and zero to 4.0 ng./ml. for the Hybritech assay) reflect two factors: a difference in assigned calibrator values and differences in the selection of the "normal" population of men used to define the normal range of values. We urge adoption of an international standard calibrator for prostate specific antigen as a means to correct these differences.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1700161     DOI: 10.1016/s0022-5347(17)39789-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

1.  The number of tPSA tests continues to rise and variation in testing practices persists: a survey of laboratory services in Ireland 2008-2010.

Authors:  F J Drummond; E Barrett; R Burns; C O'Neill; L Sharp
Journal:  Ir J Med Sci       Date:  2013-09-27       Impact factor: 1.568

2.  Equivalent recognition of free and ACT-complexed PSA in a monoclonal-polyclonal sandwich assay is conferred by binding specificity of the monoclonal antibody.

Authors:  Z Zhou; E G Armstrong; A Belenky; J V Freeman; K K Yeung
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

3.  Development of an immunoassay specific for the PSA-ACT complex without the problem of high background.

Authors:  J T Wu; P Zhang; G H Liu; L Wilson
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

4.  Bayer Immuno 1 PSA Assay: an automated, ultrasensitive method to quantitate total PSA in serum.

Authors:  D L Morris; P W Dillon; D L Very; P Ng; L Kish; J L Goldblatt; D J Bruzek; D W Chan; M S Ahmed; D Witek; H A Fritsche; C Smith; D Schwartz; M K Schwartz; J L Noteboom; R L Vessella; K K Yeung; W J Allard
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

5.  Between-subject variations of transition zone epithelial volume and serum PSA levels in men with benign prostatic hyperplasia.

Authors:  Martella Oreste; Paradiso Galatioto Giuseppe; Pace Gianna; Angelucci Adriano; Necozione Stefano; Bologna Mauro; Vicentini Carlo
Journal:  World J Urol       Date:  2009-08-19       Impact factor: 4.226

Review 6.  A brief review of ultrasensitive prostate-specific antigen assays for the evaluation of patients after radical prostatectomy.

Authors:  T K Takayama; R L Vessella; P H Lange
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

7.  Clinical implications of introducing a new PSA assay.

Authors:  Ramachandran Venkitaraman; Andrew R Norman; Jhangir Iqbal; David P Dearnaley; Alan Horwich; Robert A Huddart; Chris C Parker
Journal:  Int Urol Nephrol       Date:  2008-02-06       Impact factor: 2.370

8.  Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.

Authors:  O Nilsson; A Peter; I Andersson; K Nilsson; B Grundström; B Karlsson
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements.

Authors:  Erica L McJimpsey
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.